--- title: "Raymond James Upgrade Boosts Oscar Health Stock After Q4 Earnings" description: "Oscar Health Inc (NYSE:OSCR) shares rose after the company reported Q4 results that missed revenue and earnings expectations but provided a strong 2026 outlook. The stock gained momentum following Ray" type: "news" locale: "en" url: "https://longbridge.com/en/news/275792406.md" published_at: "2026-02-12T17:59:40.000Z" --- # Raymond James Upgrade Boosts Oscar Health Stock After Q4 Earnings > Oscar Health Inc (NYSE:OSCR) shares rose after the company reported Q4 results that missed revenue and earnings expectations but provided a strong 2026 outlook. The stock gained momentum following Raymond James' upgrade from Market Perform to Outperform, with a price target of $18. Oscar's 2026 revenue guidance of $18.7 billion to $19.0 billion significantly exceeds analysts' estimates, and the firm anticipates improved EBIT margins in the coming years. As of Thursday, OSCR shares were up 0.96% at $13.73. **Oscar Health** **Inc** (NYSE:OSCR) shares are climbing on Thursday. The company posted fourth‑quarter results that missed expectations on both revenue and earnings, but had a stronger‑than‑expected 2026 outlook. - Oscar Health stock is gaining positive traction. Why are OSCR shares climbing? ## What The Numbers Showed Oscar reported a quarterly loss of $1.24 per share, wider than the 89 cent loss analysts were expecting and a notable step back from the 62 cent loss a year ago. Revenue also came in light at $2.81 billion, below the $3.12 billion consensus, though it still marked 17% year‑over‑year growth. ## Guidance May Be Helping The Stock The company issued 2026 revenue guidance of $18.7 billion to $19.0 billion, dramatically above the Street's $12.565 billion estimate. Oscar also expects a medical loss ratio of 82.4% to 83.4% and operating earnings between $250 million and $450 million for the year. ## Raymond James Upgrade Adds Momentum Helping fuel the rally, Raymond James upgraded Oscar Health shares from Market Perform to Outperform, setting an $18 price target versus the stock's current level around $13.60, Investing.com reported. The firm called Oscar "the best house in a tough neighborhood," pointing to an attractive valuation as ACA exchange margins begin to recover. Raymond James expects Oscar to generate roughly 2% EBIT margin in 2026, expanding to around 4% in 2027 as the medical loss ratio improves through repricing and G&A efficiencies. The firm added that much of the uncertainty around ACA subsidies and integrity rules is already reflected in the stock, creating a steadier backdrop for modest margin improvement. Oscar's long‑term EPS target remains $2.25. **OSCR Price Action:** Oscar Health shares were up 0.96% at $13.73 at the time of publication on Thursday, according to Benzinga Pro. *Image: Tada Images/Shutterstock.com* ### Related Stocks - [OSCR.US - Oscar Health](https://longbridge.com/en/quote/OSCR.US.md) - [OSCG.US - Leverage Shares 2X Long OSCR Daily ETF](https://longbridge.com/en/quote/OSCG.US.md) - [OSCX.US - Defiance Daily Target 2x Long OSCR ETF](https://longbridge.com/en/quote/OSCX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Oscar Health｜10-K：2025 财年营收 117 亿美元不及预期 | | [Link](https://longbridge.com/en/news/275946059.md) | | Oscar Health｜8-K：2025 财年 Q4 营收 28.05 亿美元不及预期 | | [Link](https://longbridge.com/en/news/275448384.md) | | Oscar Health 预计尽管在 2025 年会有亏损，但在 2026 年将实现增长 | Oscar Health 已获得 4.75 亿美元的循环信贷额度，以增强流动性并支持增长。尽管预计 2025 年收入将增加至 117 亿美元，但由于医疗成本高企，公司报告了 3.964 亿美元的运营亏损。Oscar 预计 2026 年收入将 | [Link](https://longbridge.com/en/news/275451700.md) | | Molina 医疗｜10-K：2025 财年营收 454 亿美元 | | [Link](https://longbridge.com/en/news/275512865.md) | | Oscar Health 第四季度的收入未能达到分析师的预期 | Oscar Health 第四季度的收入和调整后的息税折旧摊销前利润（EBITDA）未能达到分析师的预期，收入为 28.1 亿美元，而预期为 31.2 亿美元。该公司已进入一项 4.75 亿美元的循环信贷额度，以增强其资产负债表。对于 20 | [Link](https://longbridge.com/en/news/275445989.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.